vs

Side-by-side financial comparison of CROSS COUNTRY HEALTHCARE INC (CCRN) and LATTICE SEMICONDUCTOR CORP (LSCC). Click either name above to swap in a different company.

CROSS COUNTRY HEALTHCARE INC is the larger business by last-quarter revenue ($236.8M vs $145.8M, roughly 1.6× LATTICE SEMICONDUCTOR CORP). LATTICE SEMICONDUCTOR CORP runs the higher net margin — -5.2% vs -35.0%, a 29.8% gap on every dollar of revenue. On growth, LATTICE SEMICONDUCTOR CORP posted the faster year-over-year revenue change (9.3% vs -23.6%). LATTICE SEMICONDUCTOR CORP produced more free cash flow last quarter ($44.0M vs $16.1M). Over the past eight quarters, LATTICE SEMICONDUCTOR CORP's revenue compounded faster (8.4% CAGR vs -21.0%).

GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...

Lattice Semiconductor Corporation is an American semiconductor company specializing in the design and manufacturing of low power field-programmable gate arrays (FPGAs). Headquartered in the Silicon Forest area of Hillsboro, Oregon, the company also has operations in San Jose, Calif., Shanghai, Manila, Penang, and Singapore. Lattice Semiconductor has more than 1000 employees and an annual revenue of more than $660 million as of 2022. The company was founded in 1983 and went public in 1989. It ...

CCRN vs LSCC — Head-to-Head

Bigger by revenue
CCRN
CCRN
1.6× larger
CCRN
$236.8M
$145.8M
LSCC
Growing faster (revenue YoY)
LSCC
LSCC
+32.9% gap
LSCC
9.3%
-23.6%
CCRN
Higher net margin
LSCC
LSCC
29.8% more per $
LSCC
-5.2%
-35.0%
CCRN
More free cash flow
LSCC
LSCC
$27.9M more FCF
LSCC
$44.0M
$16.1M
CCRN
Faster 2-yr revenue CAGR
LSCC
LSCC
Annualised
LSCC
8.4%
-21.0%
CCRN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CCRN
CCRN
LSCC
LSCC
Revenue
$236.8M
$145.8M
Net Profit
$-82.9M
$-7.6M
Gross Margin
68.5%
Operating Margin
-30.2%
30.7%
Net Margin
-35.0%
-5.2%
Revenue YoY
-23.6%
9.3%
Net Profit YoY
-2109.7%
14.6%
EPS (diluted)
$-2.56
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCRN
CCRN
LSCC
LSCC
Q1 26
$145.8M
Q4 25
$236.8M
Q3 25
$250.1M
$133.3M
Q2 25
$274.1M
$124.0M
Q1 25
$293.4M
$120.2M
Q4 24
$309.9M
$117.4M
Q3 24
$315.1M
$127.1M
Q2 24
$339.8M
$124.1M
Net Profit
CCRN
CCRN
LSCC
LSCC
Q1 26
$-7.6M
Q4 25
$-82.9M
Q3 25
$-4.8M
$2.8M
Q2 25
$-6.7M
$2.9M
Q1 25
$-490.0K
$5.0M
Q4 24
$-3.8M
$16.5M
Q3 24
$2.6M
$7.2M
Q2 24
$-16.1M
$22.6M
Gross Margin
CCRN
CCRN
LSCC
LSCC
Q1 26
68.5%
Q4 25
Q3 25
20.4%
67.9%
Q2 25
20.4%
68.4%
Q1 25
20.0%
68.0%
Q4 24
61.1%
Q3 24
20.4%
69.0%
Q2 24
20.8%
68.3%
Operating Margin
CCRN
CCRN
LSCC
LSCC
Q1 26
0.7%
Q4 25
-30.2%
Q3 25
-2.4%
-1.2%
Q2 25
-2.1%
3.8%
Q1 25
-0.3%
5.8%
Q4 24
-1.1%
-10.4%
Q3 24
0.9%
5.9%
Q2 24
-5.7%
18.2%
Net Margin
CCRN
CCRN
LSCC
LSCC
Q1 26
-5.2%
Q4 25
-35.0%
Q3 25
-1.9%
2.1%
Q2 25
-2.4%
2.3%
Q1 25
-0.2%
4.2%
Q4 24
-1.2%
14.1%
Q3 24
0.8%
5.7%
Q2 24
-4.7%
18.2%
EPS (diluted)
CCRN
CCRN
LSCC
LSCC
Q1 26
$-0.06
Q4 25
$-2.56
Q3 25
$-0.15
$0.02
Q2 25
$-0.20
$0.02
Q1 25
$-0.02
$0.04
Q4 24
$-0.13
$0.12
Q3 24
$0.08
$0.05
Q2 24
$-0.47
$0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCRN
CCRN
LSCC
LSCC
Cash + ST InvestmentsLiquidity on hand
$108.7M
$133.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$322.8M
$714.1M
Total Assets
$449.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCRN
CCRN
LSCC
LSCC
Q1 26
$133.9M
Q4 25
$108.7M
Q3 25
$99.1M
$117.9M
Q2 25
$81.2M
$107.2M
Q1 25
$80.7M
$127.6M
Q4 24
$81.6M
$136.3M
Q3 24
$64.0M
$124.3M
Q2 24
$69.6M
$109.2M
Stockholders' Equity
CCRN
CCRN
LSCC
LSCC
Q1 26
$714.1M
Q4 25
$322.8M
Q3 25
$408.1M
$706.4M
Q2 25
$412.2M
$687.0M
Q1 25
$418.2M
$707.9M
Q4 24
$419.0M
$710.9M
Q3 24
$424.7M
$703.5M
Q2 24
$433.3M
$698.8M
Total Assets
CCRN
CCRN
LSCC
LSCC
Q1 26
$883.1M
Q4 25
$449.0M
Q3 25
$538.2M
$844.4M
Q2 25
$553.8M
$808.6M
Q1 25
$576.2M
$823.6M
Q4 24
$589.3M
$843.9M
Q3 24
$597.4M
$853.7M
Q2 24
$602.9M
$827.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCRN
CCRN
LSCC
LSCC
Operating Cash FlowLast quarter
$18.2M
$57.6M
Free Cash FlowOCF − Capex
$16.1M
$44.0M
FCF MarginFCF / Revenue
6.8%
30.2%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$40.1M
$153.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCRN
CCRN
LSCC
LSCC
Q1 26
$57.6M
Q4 25
$18.2M
Q3 25
$20.1M
$47.1M
Q2 25
$4.2M
$38.5M
Q1 25
$5.7M
$31.9M
Q4 24
$24.2M
$45.4M
Q3 24
$7.5M
$44.0M
Q2 24
$82.4M
$21.9M
Free Cash Flow
CCRN
CCRN
LSCC
LSCC
Q1 26
$44.0M
Q4 25
$16.1M
Q3 25
$17.9M
$34.0M
Q2 25
$2.3M
$31.3M
Q1 25
$3.8M
$23.3M
Q4 24
$21.7M
$39.7M
Q3 24
$6.3M
$39.4M
Q2 24
$79.6M
$14.8M
FCF Margin
CCRN
CCRN
LSCC
LSCC
Q1 26
30.2%
Q4 25
6.8%
Q3 25
7.2%
25.5%
Q2 25
0.8%
25.2%
Q1 25
1.3%
19.4%
Q4 24
7.0%
33.8%
Q3 24
2.0%
31.0%
Q2 24
23.4%
11.9%
Capex Intensity
CCRN
CCRN
LSCC
LSCC
Q1 26
9.3%
Q4 25
0.9%
Q3 25
0.9%
9.8%
Q2 25
0.7%
5.8%
Q1 25
0.6%
7.2%
Q4 24
0.8%
4.9%
Q3 24
0.4%
3.7%
Q2 24
0.8%
5.8%
Cash Conversion
CCRN
CCRN
LSCC
LSCC
Q1 26
Q4 25
Q3 25
16.86×
Q2 25
13.23×
Q1 25
6.35×
Q4 24
2.75×
Q3 24
2.92×
6.12×
Q2 24
0.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CCRN
CCRN

Temporary Staffing Services$189.6M80%
Physician Staffing$42.5M18%
Other Services$4.7M2%

LSCC
LSCC

Segment breakdown not available.

Related Comparisons